Published 01 March 2011
Shire, a specialty biopharmaceutical company, has received the US Food and Drug Administration’s (FDA) approval to use the once-daily INTUNIV (guanfacine) Extended-Release Tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents ages 6 to 17.The approval is based on the satisfactory results obtained from a 9-week, multicenter, double-blind, randomized, placebo-controlled study of INTUNIV in combination with a stimulant in children and adolescents with ADHD.
Read the rest of the article here.
No comments:
Post a Comment